Compound class:
Synthetic organic
Comment: CFT7455 is a monofunctional IKZF1/3 degrader that was developed by C4 Therapeutics for potential to treat relapsed/refractory multiple myeloma. It is orally bioactive.
|
|
No information available. |
Summary of Clinical Use ![]() |
On-target dose-limiting toxicity was detected in phase 1 analysis. Alternative doses are being explored to try to resolve this. |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT04756726 | Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma | Phase 1/Phase 2 Interventional | C4 Therapeutics, Inc. |